SBS.L Share News (SBS)

Source BioScience Confident For Full-Year, Third Quarter Revenues Over 20% Ahead

Vindon Healthcare Says Cash Offer From Source BioScience Now Unconditional

Source BioScience Offer For Vindon Now Unconditional

Source BioScience Declares Vindon Takeover Unconditional

Vindon surges on possible sale to Source BioScience

Vindon shares surged after the healthcare company said it was in advanced talks to be bought by Source BioScience for 12.2m pounds. The proposed cash offer of 13.7p a share would value Vindon shares at 44% more than the 9.5p closing price on July 15th. Vindon shares were up 31.6% at 12.5p at 08:3

Source BioScience reports strong Q3

Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations. The company said the three months to the end of September had been a period of sustained growth and development with increased revenue in b

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Source BioScience hails strong first quarter

Diagnostics and genetic analysis firm Source BioScience has seen revenue increase by 19% in the first quarter, helped by strong growth in diagnostics and life sciences. "Overall performance for the year to date is in line with expectations, representing a continuation of the strong growth and busin

Sector movers: Pharmaceuticals up, banks down

Pharmaceuticals and biotechnology is the best performing sector today. Source Bioscience put in a solid trading performance during November and December 2010 and full year 2010 results should be in line with market expectations. "Both our LifeSciences and PharmaBiotech divisions demonstrated double

Small caps round-up: All Leisure, Wasabi Energy, Nexus...

Cruise operator All Leisure lost £2.1m in the year ended 31 October compared with a profit of £2.7m in 2009 because of one-off charges linked to the valuation of derivative used for hedging purposes. Turnover rose 12% to £82.6m thanks to a full-year contribution from Hebridean Princess and a first

Small caps round-up: Valiant Petroleum, Source BioScience, Cyril Sweett

Production at North Sea oil explorer Valiant Petroleum remains on target to hit 6,500-7,500 barrels of oil per day (bopd) in 2010, towards the upper end of its guidance range. The company has also received commitments exceeding its initial target of $350m in relation to the refinancing of its debt

Source BioScience Wins 5-Year Cervical Cancer Screening Job

LONDON (Dow Jones)--Source BioScience PLC (SBS.LN), a provider of expert, quality services to the healthcare, pharma biotech and life science research sector, said Wednesday that it has won the tender to supply cytology services to Cervical Screening Wales or CSW for the second time. MAIN FACTS: